Homes
Public Notices
News
Local news
Editor’s Pick
Pittsburgh
Local Government
Roads, Travel and Traffic
20 Years of Gas Drilling
Regional
U.S. and World
Business
Sports
HS Sports
College Sports
Penguins
Pirates
Steelers
Athlete of the Week
Wild Things
Pony Baseball
Outdoors
Columns
Opinion
Columns
Editorials
Letters to the Editor
Op Eds
Living
Neighbors
School News
Entertainment
Home and Garden
Food
Police Beat
Obituaries
Classifieds
Legal Notices
Sponsored Content
e-Edition
close
Washington County
Greene County
Mon Valley
News
Local news
Police Beat
Pittsburgh
Local Government
Roads, Travel and Traffic
Helping The Helpers
20 Years of Gas Drilling
Regional
U.S. and World
Business News
Sports
High School Sports
College Sports
Penguins
Pirates
Steelers
Wild Things
Pro Sports
Outdoors
Sports Column
Obituaries
Opinion
Columns
Editorials
Letters to the Editor
Op-Ed
Living
Neighbors
Health and Wellness
Entertainment
Home and Garden
Classifieds
Contact Us
Advertise With Us
Customer Service
Contact Information
Submission Forms
Statement of Values
Misc
Special Sections
Events
Sponsored Content
Newsletter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Sanofi - American Depositary Shares
(NQ:
SNY
)
48.63
UNCHANGED
Streaming Delayed Price
Updated: 4:00 PM EST, Feb 10, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Sanofi - American Depositary Shares
< Previous
1
2
...
27
28
29
30
31
32
33
34
35
...
40
41
Next >
Apple, Meta, Pfizer Among Key Companies Reporting In The Week Ahead, As Earning Picks Up Pace
↗
July 24, 2022
Big tech earnings will flow in thick and fast in the upcoming week, providing more clarity on how supply chain disruptions and the macroeconomic malaise have impacted these companies.
Via
Benzinga
Pasithea's Latest Drug Candidate Could Bring New Hope To ALS Patients Without Effective Treatment Options
↗
July 20, 2022
Amyotrophic lateral sclerosis (ALS) is a rare but painful and fatal disease that slowly shuts down all voluntary movements in the body, from walking to breathing.
Via
Benzinga
Analyzing Sanofi's Short Interest
↗
July 19, 2022
Sanofi's (NASDAQ:SNY) short percent of float has fallen 14.29% since its last report. The company recently reported that it has 3.00 million shares sold short, which is 0.12% of...
Via
Benzinga
Clovis Oncology (CLVS) Stock Pops 7% on Supply Agreement
↗
July 19, 2022
CLVS stock is rallying 7% after Clovis Oncology made a major deal with NorthStar Medical. Takeover speculation has swirled around Clovis.
Via
InvestorPlace
Daily Stock Analysis: Sanofi S.A.
↗
July 19, 2022
Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. It was founded in 1973 and is headquartered in Paris.
Via
Talk Markets
Sanofi's Fitusiran Prophylaxis Cuts Bleeds By 61% In Hemophilia Patients
↗
July 11, 2022
Via
Benzinga
Sanofi Dives After FDA Slaps Its $3.7 Billion Drug With A Hold
↗
June 30, 2022
The company was testing the drug in multiple sclerosis and myasthenia gravis.
Via
Investor's Business Daily
The Daily Biotech Pulse: Sesen Bio Stops Lead Assest Development In US, FDA Approves Eton Pharma's Partial Seizures Drug, Bavarian Nordic Inks Multiple Supply Pact For Monkeypox Vaccine
↗
July 18, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours:
Via
Benzinga
The Daily Biotech Pulse: Much Awaited FDA Nod For Novavax's COVID-19 Shot, DSMB Suggests ContraFect To Stop Antimicrobial-Resistant Infection Study, CytomX Restructures
↗
July 14, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours:
Via
Benzinga
Regeneron-Sanofi's Dupixent Hits Primary Goal In Esophagitis Patients Below 11 Years
↗
July 14, 2022
Via
Benzinga
Sanofi Offloads 17 Products To Neuraxpharm
↗
July 13, 2022
Sanofi SA (NASDAQ: SNY) has entered a deal to hand over 17 products to central nervous system (CNS) specialist Neuraxpharm for an undisclosed sum.
Via
Benzinga
Why Sanofi Shares Are Falling Today
↗
June 30, 2022
Via
Benzinga
The Daily Biotech Pulse: Europe Approves Second Round Of Booster Doses of mRNA COVID-19 Vaccines, Perrigo Seeks Approval For First OTC Birth Control Pill, MacroGenics Closes Head & Cancer Study After Patient Death
↗
July 11, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours:
Via
Benzinga
SOBI-Sanofi Partnered Hemophilia Therapy Shows Superior Bleed Protection Than Prior Prophylaxis
↗
July 11, 2022
Via
Benzinga
Biotech Stocks To Watch And Pharma Industry News
↗
July 08, 2022
Track the latest trends and leading stocks in the biotech and pharmaceutical industries.
Via
Investor's Business Daily
This New York-Based Digital Therapeutics Company Looks To Disrupt a $475 Billion Market
↗
July 07, 2022
As the global coronavirus pandemic forced people to keep their distance from one another, there has been an increase in the adoption of digital health solutions among healthcare professionals and...
Via
Benzinga
INVESTIGATION NOTICE: The Schall Law Firm Encourages Investors in Sanofi with Losses of $100,000 to Contact the Firm
July 05, 2022
From
The Schall Law Firm
Via
Business Wire
The Daily Biotech Pulse: AstraZeneca Goes Shopping, TYME Technologies & Syros Pharma Merger, FDA Clears Vertex Pharma's Stem Cell-Based Diabetes Therapy Study
↗
July 05, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours:
Via
Benzinga
INVESTIGATION ALERT: The Schall Law Firm Encourages Investors in Sanofi with Losses of $100,000 to Contact the Firm
July 01, 2022
From
The Schall Law Firm
Via
Business Wire
How Is The Market Feeling About Sanofi?
↗
July 01, 2022
Sanofi's (NASDAQ:SNY) short percent of float has fallen 22.22% since its last report. The company recently reported that it has 3.47 million shares sold short, which is 0.14% of...
Via
Benzinga
Attention Biotech Investors: Mark Your Calendar For These July PDUFA Dates
↗
July 01, 2022
The biotech sector is poised to end June on a positive note, despite largely disappointing regulatory decisions scheduled during the month, thanks to a reversal in broader market sentiment.
Via
Benzinga
The Daily Biotech Pulse: Pfizer/BioNTech Ink New COVID-19 Vaccine Supply Pact, Sanofi Hit By FDA Clinical Hold, Angion Biomedica Halts Second Kidney Disease Trial
↗
June 30, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours:
Via
Benzinga
Pfizer, Moderna Analysts Respond To FDA COVID Booster Ruling: 'Revenues Will Decline'
↗
June 29, 2022
The Food and Drug Administration’s panel of independent vaccine experts recently voted 19 to 2 to recommend a new batch of COVID-19 booster shots targeting the omicron variant this fall. The news,...
Via
Benzinga
Sanofi Lowers Out-Of-Pocket Insulin Cost For Uninsured Patients
↗
June 29, 2022
Via
Benzinga
Finally An Omicron-Blocking Shot? Sanofi, GSK Say Yes
↗
June 24, 2022
The companies' shot was more than 93% effective in previously infected people.
Via
Investor's Business Daily
Benzinga Before The Bell: Gun Safety Bill. Bill Gates's North Dakota Outrage, Sanofi-GSK's Covid-19 Vaccine's Omicron Efficacy And Other Top Financial Stories Friday, June 24
↗
June 24, 2022
Reuters
Via
Benzinga
Sanofi-GSK's Beta-Containing COVID-19 Vaccine Shows Efficacy Against Omicron
↗
June 24, 2022
Via
Benzinga
This Pharmaceutical Company Is Moving Beyond CBD
↗
June 23, 2022
The applications for cannabidiol (CBD) and cannabinoid-based therapeutics are many. Many novel treatments have been, and are continuing to be, discovered using these compounds. The industry is huge...
Via
Benzinga
Jupiter Wellness Believes Its Latest Strategic Acquisition Could Be A Significant Boon To Compete In The Medical Cannabis Industry
↗
June 21, 2022
Companies like Tilray Inc. (NASDAQ: TLRY) and Cara Therapeutics Inc.
Via
Benzinga
Clovis Oncology (CLVS) Stock Gains 20% on Tumor Trials, Buyout Hopes
↗
June 17, 2022
Today has been another strong one for investors in Clovis Oncology and CLVS stock, with this company surging another 20% in today's session.
Via
InvestorPlace
< Previous
1
2
...
27
28
29
30
31
32
33
34
35
...
40
41
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
Starting at $3.75
/
week.
Subscribe Today